VENLO, The Netherlands, January 18, 2018 /PRNewswire/ --
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA)plans as previously announced to release its report on results for the fourth quarter and full-year 2017 on Wednesday, January 31, at approximately 22:05 Central European Time (CET) / 16:05 Eastern
Conference Call and Webcast Details The conference call will begin at 15:00 CET / 9:00 EST on February 1, 2018. Interested parties may listen to the call by dialing: +1 760 294 1674 (U.S.), +44 203 059 5869 (UK), +49 69 566 037 000 (Germany) The webcast will be accessible at http://www.qiagen.com/de/about-us/investors/corporate-calendar.
A conference call replay will be available by using the following link: http://services.choruscall.eu/links/qiagen180201.html
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharma and biotech companies) and Academia (life sciences research). As of December 31, 2017, QIAGEN employed approximately 4,600 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.
Contact: John Gilardi Vice President Corporate Communications and Investor Relations +49-2103-29-11711 +1-240-686-2222 Email: email@example.com
Dr. Sarah Fakih Associate Director Investor Relations +49-2103-29-11457 Email: firstname.lastname@example.org
SOURCE Qiagen N.V.
Subscribe to our Free Newsletters!
Birth Control Implant is a long-acting birth control contraceptive inserted into the arm. It is a ...
Mastocytosis is a rare condition marked by accumulation of mast cells under the skin and various ...
Lusutrombopag is used to treat abnormally low platelet counts (thrombocytopenia) in adult patients ...View All